Active	Status	Sponsor type	Region	Phase	Filter
61 Active 82 Inactive 143 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Wang, Bo
PRESERVE-003, NCT05671510: ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors	Active, not recruiting	3	600	Europe, Canada, US, RoW	Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere	OncoC4, Inc., BioNTech SE	Non Small Cell Lung Cancer	06/26	06/27
Be6A Lung-01, NCT06012435: A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer ().	Recruiting	3	600	Europe, Canada, Japan, US, RoW	sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel	Seagen Inc.	Carcinoma, Non-Small-Cell Lung	07/26	07/28
Acclaim-3, NCT05703971: Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients	Recruiting	1/2	62	US	quaratusugene ozeplasmid, REQORSA, atezolizumab, TECENTRIQ	Genprex, Inc.	Small Cell Lung Cancer Extensive Stage	02/26	08/27
Mutale, Wilbroad
No trials found
Zyambo, Cosmas
No trials found
Zulu, Richard
No trials found
Sampa, Mutale
No trials found
Zulu, Joseph
No trials found